secwatch.observer — SEC 8-K summary
======================================

Issuer:     Embecta Corp. (EMBC)
CIK:        0001872789
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001872789-23-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Embecta Q4 revenue $281.9M (+2.7%); guides FY2024 revenue down 1-3%
-------------------------------------------------------------------

- Q4 GAAP EPS $0.10, adjusted EPS $0.59; full-year adjusted EPS $2.99.
- FY2024 revenue guidance $1,085-1,105M (reported -3% to -1%); adj. EPS $1.90-$2.10.
- Dividend declared $0.15/share, payable Dec 15, 2023, record Dec 4.
- Added as exclusive/dual-preferred brand with three top Medicare Part D payers starting Jan 2024.
- Type 2 closed loop insulin pump development on track with FDA Breakthrough Device Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1872789/000187278923000029/0001872789-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1872789/000187278923000029/embc-20231121.htm
  HTML page:      https://secwatch.observer/filing/0001872789-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer